{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fconnected-intelligence.simplecast.com%2Fepisodes%2Fdawn-bell-on-smart-risk-APJ4_HeW","width":444,"version":"1.0","type":"rich","title":"Dawn Bell on Smart Risk","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/eacedbe8-d939-436e-900f-95b933c8ff83/a3d3d78b-9ce3-4b7d-a391-d31d919210da/dawn-header.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/614ddd8a-00e6-452c-82b7-ee769a6c7fcd\" height=\"200\" width=\"100%\" title=\"Dawn Bell on Smart Risk\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Dr. Dawn Bell is the Global Development Head, Strategic Partnerships at Novartis, a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide. Novartis - one of the largest pharmaceutical companies in the world - is where Dawn leads business development and portfolio strategy for whitespace opportunities. Working in large pharma, mid-sized, and start-up companies, she has developed and launched 12 innovative medicines across 8 therapeutic areas. Dawn is energized by working with and advising founders and start-up CEOs through her role as a Mentor at Creative Destruction Lab, and Executive Council member in EIT Health’s Gold Track Program (Germany). She serves as a board advisor to two privately held, venture-backed drug discovery companies and board director for The Metabolomics Innovation Center, a nationally funded research facility based in Alberta, Canada."}